1. Home
  2. KRYS vs NAKA Comparison

KRYS vs NAKA Comparison

Compare KRYS & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • NAKA
  • Stock Information
  • Founded
  • KRYS 2015
  • NAKA 2019
  • Country
  • KRYS United States
  • NAKA United States
  • Employees
  • KRYS N/A
  • NAKA N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • NAKA
  • Sector
  • KRYS Health Care
  • NAKA
  • Exchange
  • KRYS Nasdaq
  • NAKA Nasdaq
  • Market Cap
  • KRYS 4.3B
  • NAKA 3.8B
  • IPO Year
  • KRYS 2017
  • NAKA 2024
  • Fundamental
  • Price
  • KRYS $155.71
  • NAKA $1.24
  • Analyst Decision
  • KRYS Strong Buy
  • NAKA Strong Buy
  • Analyst Count
  • KRYS 9
  • NAKA 1
  • Target Price
  • KRYS $203.22
  • NAKA $8.00
  • AVG Volume (30 Days)
  • KRYS 295.3K
  • NAKA 8.6M
  • Earning Date
  • KRYS 11-03-2025
  • NAKA 11-11-2025
  • Dividend Yield
  • KRYS N/A
  • NAKA N/A
  • EPS Growth
  • KRYS 36.22
  • NAKA N/A
  • EPS
  • KRYS 4.91
  • NAKA N/A
  • Revenue
  • KRYS $359,205,000.00
  • NAKA $2,239,936.00
  • Revenue This Year
  • KRYS $34.33
  • NAKA N/A
  • Revenue Next Year
  • KRYS $47.84
  • NAKA N/A
  • P/E Ratio
  • KRYS $31.68
  • NAKA N/A
  • Revenue Growth
  • KRYS 116.08
  • NAKA N/A
  • 52 Week Low
  • KRYS $122.80
  • NAKA $0.65
  • 52 Week High
  • KRYS $207.84
  • NAKA $34.77
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 60.39
  • NAKA 33.52
  • Support Level
  • KRYS $136.73
  • NAKA $3.26
  • Resistance Level
  • KRYS $152.96
  • NAKA $8.58
  • Average True Range (ATR)
  • KRYS 5.13
  • NAKA 1.30
  • MACD
  • KRYS 0.11
  • NAKA -0.34
  • Stochastic Oscillator
  • KRYS 97.23
  • NAKA 0.93

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About NAKA Kindly MD Inc. Common Stock

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

Share on Social Networks: